Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety and effectiveness monitoring of sintilimab in relapsed or refractory classical Hodgkin lymphoma
CTR20201421Phase 4Active
- Sponsor
- InnoCare Pharma
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of sintilimab in classical Hodgkin lymphoma (cHL), sponsored by InnoCare Pharma. Started Apr 2020; status: active.
02
Drugs
sintilimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20201421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201421.